← ALL EPISODES

INTERVIEW SNAPSHOT · COVERED IN THE REPORT'S SECTION 10 · VENTURE 3.0

Democratisation of Venture Capital

What if the future of venture didn't belong to institutions, but to millions of retail people backing deeptech from their own portfolios?

MAY 202551 MINGUEST · MICHAEL MOTSCHMANN

10K 1M SNAPSHOT
We're not just funding companies, we're helping Europe stay independent through innovation.
Michael Motschmann · on what MIG is really funding
PRESS PLAY TO LOAD THE VIDEO. NOTHING IS REQUESTED FROM YOUTUBE UNTIL YOU DO.
€1B+Venture platform based in Munich
Fund 18Now in fundraising; Fund 17 closed last year at €110M, against a first fund of €30M started in 2004
€10K–€1MTicket range for the retail individuals who make up the LP base
€1.3BTotal purchase price, up to, for Ganymed, sold to Astellas in 2016
ABOUT THE EPISODE

Rohit Yadav sits down with Michael Motschmann, Founder & Managing Partner at MIG Capital, a €1B+ venture platform based in Munich with one of the most unique LP bases in Europe: everyday retail investors. From backing BioNTech at inception to building Fund 18, Michael has pioneered a people-first venture model, well before "democratization" became a buzzword.

We unpack:

  • The founding of BioNTech, and how MIG helped shape one of the most impactful companies in medical history.
  • Why MIG raises venture capital from retail investors, not institutions.
  • How Germany's banking DNA shaped its late start in VC.
  • What Europe needs to compete globally: capital market reform, defense tech, and homegrown IPOs.
  • How deep tech, from semiconductors to oncology, will anchor Europe's next growth wave.
  • Why AI is a tool, not a substitute, for founders, scientists, or fund managers.

We also dive into:

  • Why family offices often understand risk better than institutions.
  • The "hidden potential" of Germany's scientific ecosystem.
  • How capital flows need to change to support European strategic autonomy.
  • Why now is the right time to enter venture, despite macro uncertainty.
  • What every investor can learn from MIG's 20-year journey through cycles, exits, and conviction.
IN HIS WORDS
MENTIONED

COMPANIES & FUNDS

FIRM

MIG Capital

Munich-based deep tech investor, life sciences, energy efficiency and semiconductors, focused on the German-speaking region and wider Europe.

PORTFOLIO

BioNTech

Founded with MIG in 2008 as an oncology company.

EXIT

Ganymed → Astellas

The first company of the two scientific founders, backed in 2007, developing a monoclonal antibody against cancer; sold to Astellas in 2016 for a total purchase price of up to 1.3 billion.

EXIT

Infineon

Buyer of the semiconductor company MIG formed out of the idea of two Harvard postdocs to cut wafer production costs by 50% or more; it took about seven years to get there.

TECHNOLOGY

InstaDeep

AI company in England bought by BioNTech, used in early detection of biopharmaceutical information from hit to lead to candidate.

PEOPLE

GUEST

Michael Motschmann

Founder & Managing Partner, MIG Capital.

HOST

Rohit Yadav

Investments thought leader, Big Book of VC.

CONTEXT

MARKET

Neue Markt collapse

The 2000–2001 crash that left German venture devastated when MIG started in 2004.

REGULATION

Basel rules

Basel I, II and III tightened the bank–customer relationship from the 1980s, and venture capital became a more prominent substitute source of finance.

SNAPSHOT

Democratisation of Venture Capital →

The full written snapshot of this interview on the Rethink site.

RELATED SNAPSHOTS